Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and provided an update on its corporate activities and product pipeline.

“The first quarter of 2018 marked a significant step forward for Cidara. We reported positive topline results from our STRIVE Phase 2 clinical trial, and continued outreach to the medical and scientific communities with important rezafungin data,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “These data position us to advance rezafungin into Phas…


Leave a Reply

Your email address will not be published.